Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › pazopanib

pazopanib

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of pazopanib

63 trials tracked of pazopanib: 9 in phase 3 or 4 and 2 with published results. The most-cited published study has 69 citations.

63Trials tracked
9Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 1 Phase 3 8 Phase 2 48 Phase 1 5 Other / NA 1
  1. Phase 3 A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) Completed · 69 cited
  2. Phase 3 Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302) Completed · 24 cited
  3. Phase 4 VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK Completed
  4. Phase 3 Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma Completed
  5. Phase 3 Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer Completed
  6. Phase 3 Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer Completed
Show 44 more trials
  1. Phase 3 Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy Completed
  2. Phase 3 Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma Completed
  3. Phase 3 Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed
  4. Phase 2 Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas Completed
  5. Phase 2 Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian Women Completed
  6. Phase 2 Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab Completed
  7. Phase 2 Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib Completed
  8. Phase 2 Pazopanib in Treating Patients With Recurrent Glioblastoma Completed
  9. Phase 2 Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma Completed
  10. Phase 2 Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma Completed
  11. Phase 2 Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC) Completed
  12. Phase 2 Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Completed
  13. Phase 2 Pazopanib as Single Agent in Advanced NETs Completed
  14. Phase 2 A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection Completed
  15. Phase 2 Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery Completed
  16. Phase 2 Pazopanib in Treating Patients With Malignant Pleural Mesothelioma Completed
  17. Phase 2 Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal Cancer Completed
  18. Phase 2 A Study of Vascular Endothelial Growth Factor (VEGF) Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer Completed
  19. Phase 2 Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer Completed
  20. Phase 2 Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer Completed
  21. Phase 2 Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer Completed
  22. Phase 2 Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer Completed
  23. Phase 2 Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery Completed
  24. Phase 2 Neoadjuvant Pazopanib in Renal Cell Carcinoma Completed
  25. Phase 2 Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer Completed
  26. Phase 2 Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer Completed
  27. Phase 2 Pazopanib in Treating Patients With Recurrent or Metastatic Breast Cancer Completed
  28. Phase 2 Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy Completed
  29. Phase 2 Pazopanib Hydrochloride in Treating Patients With Von Hippel-Lindau Syndrome Completed
  30. Phase 2 Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma Completed
  31. Phase 2 Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment Completed
  32. Phase 2 Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer Completed
  33. Phase 2 To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD Completed
  34. Phase 2 Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma Completed
  35. Phase 2 Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer Completed
  36. Phase 2 Pazopanib in Treating Patients With Metastatic Urothelial Cancer Completed
  37. Phase 2 Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors Completed
  38. Phase 2 An Extension to Study MD7108240 Completed
  39. Phase 2 Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma Completed
  40. Phase 2 Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab Completed
  41. Phase 2 Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer Completed
  42. Phase 2 Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial Completed
  43. Phase 2 Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer Completed
  44. Phase 2 Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer Completed

Showing the 50 most-cited and recently-updated of 63 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Pazopanib and Axitinib Linked to Probable Cholecystitis in Renal Cell Carcinoma Case
Drug Pipeline Sys. Review
Pazopanib and Axitinib Linked to Probable Cholecystitis in Renal Cell Carcinoma Case Kidney cancer drugs may cause gallbladder inflammation in some patients
This case report and literature review describes a 74-year-old man with renal cell carcinoma who developed cholecystitis 4 weeks after start…
A 74-year-old man developed gallbladder inflammation after taking two specific drugs for kidney cancer, highlighting a need for closer monit…
Frontiers Sep 15, 2026
Protocol for a systematic review and network meta-analysis of second-line soft tissue sarcoma treatments
Oncology Meta-analysis
Protocol for a systematic review and network meta-analysis of second-line soft tissue sarcoma treatments Protocol outlines options for second-line soft tissue sarcoma treatments
This is a protocol for a systematic review and network meta-analysis. It will evaluate second-line pharmacological regimens for advanced sof…
A new protocol maps second-line drug choices for advanced soft tissue sarcoma patients previously treated with anthracyclines, noting curren…
medRxiv May 24, 2026